MOv19-BBz CAR-T cells Therapy

N/A

Report date: 2025/08/13 20:02:02

Base Information

Drug NameMOv19-BBz CAR-T cells Therapy

Drug Alias NameMOv19-BBz CAR T cells

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionFolate receptor alpha modulators

TargetsFolate receptor alpha

Therapy Area/IndicationsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Pennsylvania

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Pennsylvania

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell Lung

Inactive IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms

Other Information

ATC CodeN/A